Innate Pharma posts €5.7 million H1 revenue
Innate Pharma (NASDAQ:IPHA) reported revenue and other income of €5.7 million for the first half of 2026, while posting a net loss of €19.6 million as the biotechnology company adjusted its research and development activities.










